RNA interference, Biotechnology, Drug, Virus, Roe v. Wade, Medicine
David Liu's lab develops next-gen base editors, small enough to fit into single AAV
Researchers use adeno-associated viruses (AAVs) as vehicles to deliver CRISPR/Cas systems, correct gene copies and DNA and RNA sequences into human cells as treatment modalities. But the size of the viruses themselves has been a limiting factor for cargo that can be stuffed into it. ...
David Liu's lab develops next-gen base editors, small enough to fit into single AAV
Researchers use adeno-associated viruses (AAVs) as vehicles to deliver CRISPR/Cas systems, correct gene copies and DNA and RNA sequences into human cells as treatment modalities. But the ...
We are sorry, we could not find the related article
If you are curious about Biotech and Career and Jobs
Please click on:
Subscribe to Biotech - Career and Jobs
What can Merck afford to buy now? ‘ANYTHING’ it wants
With Keytruda bulling its way past the $5 billion mark for Q2 sales, you could say that the top execs at Merck can be believed when they say how keenly interested they are in using its cash ...
Biotech Takes a Stand
Not long ago, biotech leaders steered clear of commenting on the issues of the day. Politics was limited to certain vested interests like drug pricing, science funding, and FDA regulation. ...
Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the
First gene-editing treatment injected into the blood reduces toxic protein for up to 1 year
Long-lasting effects of CRISPR infusion suggest patients’ neurological symptoms should improve
Moderna-partnered gene editor Metagenomi adds $175M to crown from Bayer, BMS and others to get into clinic, launch new biotechs
Bayer and Moderna have already signaled confidence in Metagenomi's CRISPR gene editing. Now, Bristol Myers Squibb, Novo Nordisk and a crop of VC shops have also made a $175 million bet on ...
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Venture capitalists vet hundreds of startups each year, looking for the best and brightest companies. Here are the biotechs they think will take off.
Ten Years of CRISPR
This month marks ten years since CRISPR-Cas9 was repurposed as a gene editing system, so we’re looking back at what has been accomplished in a decade of CRISPR editing.